Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenaKumab in Active Systemic Juvenile Idiopathic Arthritis
NCT05925452Phase 3Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of genakumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Proportion of subjects with successful glucocorticoid reduction at 24 weeks. Started Dec 2023; status: recruiting.
02
Drugs
genakumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT05925452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925452.